<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139032</url>
  </required_header>
  <id_info>
    <org_study_id>APD334-006</org_study_id>
    <nct_id>NCT03139032</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations</brief_title>
  <official_title>A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the&#xD;
      efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active&#xD;
      skin extra-intestinal manifestations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to terminate the study&#xD;
  </why_stopped>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Actual">December 6, 2017</completion_date>
  <primary_completion_date type="Actual">December 6, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Proof of concept, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Endoscopic Improvement/Histologic Healing Using Endoscopy or Flexible Proctosigmoidoscopy</measure>
    <time_frame>Weeks 12</time_frame>
    <description>Only if there are signs of inflammation at screening another evaluation was planned to be performed at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Level of Fecal Calprotectin</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Extra-intestinal Manifestations (EIM) (PG, EN and Psoriasis)</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin EIM</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in the Dermatology Life Quality Index Score</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Inflammatory Bowel Disease Questionnaire Score</measure>
    <time_frame>Weeks 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in C-reactive Protein</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12 and the 2-week follow-up visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Leucocyte Characterization</measure>
    <time_frame>Weeks 8 and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Stool Frequency at Ulcerative Colitis Endpoint</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Rectal Bleeding at Ulcerative Colitis Endpoint</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Physicians Global Assessments at Ulcerative Colitis Endpoint</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Lymphocyte Counts</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Disease Activity Score at Crohn's Disease Endpoint</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Change From Baseline in Psoriasis Area and Severity Index at Psoriasis Endpoint</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint - Changes in Degree of Immune Cell Infiltration as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)</measure>
    <time_frame>Weeks -1, 8, and 12.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exploratory Endpoint -Changes in Levels of Cytokine Expression as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)</measure>
    <time_frame>Weeks -1, 8 and 12.</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Safety Measured by Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>From date of first dose of study treatment to the safety follow-up visit, approximately 14 weeks</time_frame>
    <description>Planned safety evaluations included clinical laboratory tests (chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and oral temperature), physical examination (assessment of general appearance, skin, head [eyes, ears, nose and throat], neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities, and body weight), 12-lead electrocardiograms, adverse event reporting, concomitant medication, and lymphocyte counts.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Skin Extra-intestinal Manifestations</condition>
  <arm_group>
    <arm_group_label>APD334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD334 active treatment for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD334</intervention_name>
    <description>APD334 active treatment for 12 weeks.</description>
    <arm_group_label>APD334</arm_group_label>
    <other_name>Etrasimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female (18-80 years).&#xD;
&#xD;
          2. Able to provide a signed informed consent prior to any study related procedure being&#xD;
             conducted.&#xD;
&#xD;
          3. Considered to be in stable health in the opinion of the investigator as determined by:&#xD;
&#xD;
               1. A pre-study physical examination with no clinically significant abnormalities&#xD;
                  unrelated to IBD.&#xD;
&#xD;
               2. Vital signs at screening: pulse rate ≥ 55 bpm, systolic blood pressure ≥ 90, and&#xD;
                  diastolic blood pressure ≥ 55 mmHg.&#xD;
&#xD;
               3. Liver function tests (ALT/AST, bilirubin and alkaline phosphatase) &lt; 2x the upper&#xD;
                  limit of normal.&#xD;
&#xD;
               4. All other pre-study clinical laboratory findings within normal range, or if&#xD;
                  outside of the normal range are not deemed clinically significant in the opinion&#xD;
                  of the investigator.&#xD;
&#xD;
               5. 12-lead electrocardiogram showing no clinically significant abnormalities in the&#xD;
                  opinion of the investigator (for confirmation please refer to exclusion criterion&#xD;
                  # 22).&#xD;
&#xD;
               6. A chest x- ray showing no evidence of active pulmonary disease (a chest x-ray&#xD;
                  taken within the previous 12 months from the screening visit may also be used).&#xD;
&#xD;
               7. Ophthalmology evaluation (by an ophthalmologist) without evidence of macular&#xD;
                  edema, supported with optical coherence tomography where available (dependent on&#xD;
                  site capability) no later than 3 months prior to screening.&#xD;
&#xD;
          4. Patients receiving stable treatment for IBD and EIM.&#xD;
&#xD;
          5. Diagnosis of active psoriasis, erythema nodosum or pyoderma gangrenosum by&#xD;
             Investigator assessments. After the enrollment of 10 patients with active EIM,&#xD;
             patients with active psoriasis due to anti TNF-alpha therapy can also be included.&#xD;
&#xD;
          6. Diagnosis of ulcerative colitis or Crohn's disease established prior to screening by&#xD;
             clinical and endoscopic evidence.&#xD;
&#xD;
          7. Eligible male and female patients must agree not to participate in a conception&#xD;
             process (i.e. active attempt to let female partner to become pregnant or to&#xD;
             impregnate, sperm donation, oocyte donation, in vitro fertilization) for at least 30&#xD;
             days after the last dose of study drug.&#xD;
&#xD;
        Non-sterile patients who are sexually active must take adequate contraception measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of abdominal abscess or toxic megacolon at the screening visit.&#xD;
&#xD;
          2. Patients with history of extensive colitis or pancolitis (duration &gt; 8 years) or&#xD;
             left-sided colitis (duration &gt; 12 years) must have documented evidence that a&#xD;
             surveillance colonoscopy was performed within 12 months of the initial screening visit&#xD;
             (if not, the patient should undergo a colonoscopy in lieu of a flexible&#xD;
             proctosigmoidoscopy during screening).&#xD;
&#xD;
          3. Previous extensive colonic resection (subtotal or total colectomy).&#xD;
&#xD;
          4. Current evidence of adenomatous colonic polyps that have not been removed.&#xD;
&#xD;
          5. Current evidence of colonic mucosal dysplasia.&#xD;
&#xD;
          6. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine or stoma.&#xD;
&#xD;
          7. Clinical significant infection as judged by the investigator in the previous 6 weeks&#xD;
             before enrollment.&#xD;
&#xD;
          8. Evidence of or treatment for C. difficile infection within 60 days, or other&#xD;
             intestinal pathogen within 30 days, prior to randomization.&#xD;
&#xD;
          9. Exposure to natalizumab or rituximab within 5 half-lives prior to randomization.&#xD;
&#xD;
         10. Treatment of underlying disease within 30 days prior to randomization (5-ASA,&#xD;
             corticosteroids, TNF-alpha inhibitors, probiotics, antidiarrheals, azathioprine and&#xD;
             6-mercaptopurine may be allowed under certain conditions).&#xD;
&#xD;
         11. Receipt of any investigational agent within 30 days or 5 half-lives (whichever is&#xD;
             longer) prior to randomization.&#xD;
&#xD;
         12. Currently require or are anticipated to require surgical intervention for IBD during&#xD;
             the study.&#xD;
&#xD;
         13. Abnormal (&lt; 80% of predicted values) forced expiratory volume (FEV1) or forced vital&#xD;
             capacity (FVC).&#xD;
&#xD;
         14. Infection with hepatitis C virus anytime in the past; confirmed active infection with&#xD;
             hepatitis B virus at screening.&#xD;
&#xD;
         15. Active or latent tuberculosis (TB), regardless of treatment history, as evidenced by&#xD;
             any of the following:&#xD;
&#xD;
               1. History of TB&#xD;
&#xD;
               2. A positive diagnostic TB test within one month of randomization&#xD;
&#xD;
               3. Chest X-ray within 12 months of randomization in which active or latent TB cannot&#xD;
                  be excluded.&#xD;
&#xD;
         16. Any known history of congenital or acquired immunodeficiency.&#xD;
&#xD;
         17. Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis)&#xD;
             within 30 days prior to randomization.&#xD;
&#xD;
         18. Recent history (within 6 months of screening visit) of cardio- or cerebrovascular&#xD;
             disease, acute coronary syndrome, myocardial infarction, unstable angina,&#xD;
             cerebro-vascular accident, including transient ischemic attack.&#xD;
&#xD;
         19. Any surgical procedure requiring general anesthesia within 30 days prior to&#xD;
             randomization or plans to undergo major surgery during the study period.&#xD;
&#xD;
         20. History of retinal macular edema.&#xD;
&#xD;
         21. History of or signs and symptoms of progressive multifocal leukoencephalopathy (PML)&#xD;
             as assessed by the PML checklist.&#xD;
&#xD;
         22. History or presence of cardiac arrhythmia, conduction system disease, or use of Class&#xD;
             Ia or Class III anti arrhythmic agents, or baseline QTc ≥ 500 msec.&#xD;
&#xD;
         23. Infection requiring hospitalization or intravenous antimicrobial therapy, or&#xD;
             opportunistic infection within 4 weeks of screening.&#xD;
&#xD;
         24. History of more than one episode of herpes zoster or any episode of disseminated&#xD;
             zoster.&#xD;
&#xD;
         25. Without documented positive varicella zoster virus (VZV) IgG antibody status or who&#xD;
             have completed VZV vaccination within 30 days prior to randomization.&#xD;
&#xD;
         26. Receipt of live vaccine within 4 weeks prior to screening.&#xD;
&#xD;
         27. History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative&#xD;
             disorder, or multiple myeloma.&#xD;
&#xD;
         28. History of malignancy except for adequately treated basal cell skin cancer.&#xD;
&#xD;
         29. History of severe allergic or anaphylactic reactions requiring medical attention.&#xD;
&#xD;
         30. Current or recent history (within one year prior to randomization) of alcohol&#xD;
             dependence or illicit drug use.&#xD;
&#xD;
         31. History of clinically significant leukopenia or lymphopenia at screening.&#xD;
&#xD;
         32. Active psychiatric problems that, in the investigator's opinion, may interfere with&#xD;
             compliance with the study procedures.&#xD;
&#xD;
         33. History of any clinically significant medical condition that, in the investigator's&#xD;
             opinion, would preclude participation in the study.&#xD;
&#xD;
         34. Use of moderate to strong inhibitors of CYP2C9.&#xD;
&#xD;
         35. History of severe renal or hepatic impairment.&#xD;
&#xD;
         36. Inability to attend all the study visits or comply with study procedures.&#xD;
&#xD;
         37. Prior exposure to etrasimod (APD334).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arena 2001</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arena 1001</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arena 3001</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <results_first_submitted>December 5, 2020</results_first_submitted>
  <results_first_submitted_qc>December 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <disposition_first_submitted>May 13, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>May 13, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 16, 2019</disposition_first_posted>
  <last_update_submitted>December 5, 2020</last_update_submitted>
  <last_update_submitted_qc>December 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03139032/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etrasimod</title>
          <description>Participants received active treatment for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etrasimod</title>
          <description>Participants received active treatment for 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Between 18 to 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Reporting demographic results for this study in which a single participant was enrolled introduces the risk of participant identification. In order to protect the participant's privacy, results for the study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Reporting demographic results for this study in which a single participant was enrolled introduces the risk of participant identification. In order to protect the participant's privacy, results for the study cannot be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The demographics of the study doesn't support the reporting of results for a single participant without running a risk of participant re-identification. In order to protect the participant's privacy, results for this study cannot be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Endoscopic Improvement/Histologic Healing Using Endoscopy or Flexible Proctosigmoidoscopy</title>
        <description>Only if there are signs of inflammation at screening another evaluation was planned to be performed at week 12.</description>
        <time_frame>Weeks 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Endoscopic Improvement/Histologic Healing Using Endoscopy or Flexible Proctosigmoidoscopy</title>
          <description>Only if there are signs of inflammation at screening another evaluation was planned to be performed at week 12.</description>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Level of Fecal Calprotectin</title>
        <time_frame>Weeks 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Level of Fecal Calprotectin</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Extra-intestinal Manifestations (EIM) (PG, EN and Psoriasis)</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Extra-intestinal Manifestations (EIM) (PG, EN and Psoriasis)</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin EIM</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin EIM</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in the Dermatology Life Quality Index Score</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in the Dermatology Life Quality Index Score</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Inflammatory Bowel Disease Questionnaire Score</title>
        <time_frame>Weeks 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Inflammatory Bowel Disease Questionnaire Score</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in C-reactive Protein</title>
        <time_frame>Weeks 1, 2, 4, 8, 12 and the 2-week follow-up visit</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in C-reactive Protein</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Leucocyte Characterization</title>
        <time_frame>Weeks 8 and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Leucocyte Characterization</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Stool Frequency at Ulcerative Colitis Endpoint</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Stool Frequency at Ulcerative Colitis Endpoint</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Rectal Bleeding at Ulcerative Colitis Endpoint</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Rectal Bleeding at Ulcerative Colitis Endpoint</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Physicians Global Assessments at Ulcerative Colitis Endpoint</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Physicians Global Assessments at Ulcerative Colitis Endpoint</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Lymphocyte Counts</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received one active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Lymphocyte Counts</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Disease Activity Score at Crohn's Disease Endpoint</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Disease Activity Score at Crohn's Disease Endpoint</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Change From Baseline in Psoriasis Area and Severity Index at Psoriasis Endpoint</title>
        <time_frame>Weeks 1, 2, 4, 8, and 12</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Change From Baseline in Psoriasis Area and Severity Index at Psoriasis Endpoint</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint - Changes in Degree of Immune Cell Infiltration as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)</title>
        <time_frame>Weeks -1, 8, and 12.</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). To protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint - Changes in Degree of Immune Cell Infiltration as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). To protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exploratory Endpoint -Changes in Levels of Cytokine Expression as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)</title>
        <time_frame>Weeks -1, 8 and 12.</time_frame>
        <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Endpoint -Changes in Levels of Cytokine Expression as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)</title>
          <population>Efficacy analyses were not conducted due to low enrollment (N=1). In order to protect participant's privacy, the results from a single participant cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety Measured by Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>Planned safety evaluations included clinical laboratory tests (chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and oral temperature), physical examination (assessment of general appearance, skin, head [eyes, ears, nose and throat], neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities, and body weight), 12-lead electrocardiograms, adverse event reporting, concomitant medication, and lymphocyte counts.</description>
        <time_frame>From date of first dose of study treatment to the safety follow-up visit, approximately 14 weeks</time_frame>
        <population>There were no analysis populations in the single participant study. Safety results for the single participant are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Etrasimod</title>
            <description>Participants received active treatment for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measured by Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>Planned safety evaluations included clinical laboratory tests (chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and oral temperature), physical examination (assessment of general appearance, skin, head [eyes, ears, nose and throat], neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities, and body weight), 12-lead electrocardiograms, adverse event reporting, concomitant medication, and lymphocyte counts.</description>
          <population>There were no analysis populations in the single participant study. Safety results for the single participant are reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study treatment until the follow-up safety visit, approximately 14 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etrasimod</title>
          <description>Participants received active treatment for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Due to limited enrollment (N=1), this clinical trial was terminated by the Sponsor and no efficacy analyses were conducted. To protect the single participant's privacy, demography and efficacy data are not reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Head of Document Operations</name_or_title>
      <organization>Arena Pharmaceuticals, Inc.</organization>
      <phone>858-453-7200</phone>
      <email>ct.gov@arenapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

